Representative maximum-intensity projection PET images of a healthy human volunteer injected with 64Cu-NOTA-EB-RGD at 1, 8, and 24 hours after injection. Axial MRI and PET slices of glioblastoma patient injected with 64Cu-NOTA-EB-RGD at different time points after injection. Image courtesy of Jingjing Zhang et al., Peking Union Medical College Hospital, Beijing, China/ Xiaoyuan Chen et al., Laboratory of Molecular Imaging and Nanomedicine, NIBIB/NIH, Bethesda, USA

Representative maximum-intensity projection PET images of a healthy human volunteer injected with 64Cu-NOTA-EB-RGD at 1, 8, and 24 hours after injection. Axial MRI and PET slices of glioblastoma patient injected with 64Cu-NOTA-EB-RGD at different time points after injection. Image courtesy of Jingjing Zhang et al., Peking Union Medical College Hospital, Beijing, China/ Xiaoyuan Chen et al., Laboratory of Molecular Imaging and Nanomedicine, NIBIB/NIH, Bethesda, USA


July 15, 2020 — A first-in-human study presented at the Society of Nuclear Medicine and Molecular Imaging 2020 Annual Meeting has demonstrated the safety, favorable pharmacokinetic and dosimetry profile of 64Cu-EBRGD, a new, relatively long-lived PET tracer, in patients with glioblastomas. The radiotracer proved to be a superior, high-contrast imaging diagnostic in patients, visualizing tumors that express low or moderate levels of αvβ3 integrin with high sensitivity.

Glioblastoma is the most common and most aggressive primary malignant brain tumor in adults, with 17,000 diagnoses annually. It is a highly diffuse and invasive disease that is personally devastating and virtually incurable. Once diagnosed, most patients survive less than 15 months, and fewer than five percent survive five years.

The 64Cu-EBRGD radiotracer presented in this study has several unique qualities. The peptide sequence Arg-Gly-Asp (RGD) specifically targets the cell surface receptor αvβ3 integrin, which is overexpressed in glioblastomas. To slow clearance, Evans Blue (EB) dye, which reversibly binds to circulating albumin, is bound to RGD, significantly enhancing target accumulation and retention. The addition of the 64Cu label to EBRGD provides persistent, high-contrast diagnostic images in glioblastoma patients.

This first-in-human, first-in-class study included three healthy volunteers who underwent whole-body 64Cu-EBRGD PET/CT. Safety data — including vital signs, physical examination, electrocardiography, laboratory parameters and adverse events--were collected after one day and after one week. Regions of interest were drawn, time-activity curves were obtained and dosimetry was calculated. Two patients with recurrent glioblastoma also underwent 64Cu-EBRGD PET/CT. Seven sets of brain PET and PET/CT scans were obtained over two consecutive days. Tumor-to-background ratios were calculated for the target tumor lesion and normal brain tissue. One week after radiotracer administration, the patient underwent surgical treatment, and immunohistochemical staining of tumor samples was performed.

64Cu-EBRGD was well-tolerated in patients with no adverse symptoms immediately or up to one week after administration. The mean effective dose of 64Cu-EBRGD was very similar to the effective dose of an 18F-FDG scan. Injection of 64Cu-EBRGD to the patients with recurrent glioblastoma showed high accumulation at the tumor with continuously increased tumor-to-background contrast over time. Post-operative pathology revealed World Health Organization grade IV glioblastoma, and immunohistochemical staining showed moderate expression of the αvß3 integrin.

"In this study, we have demonstrated a potential radiotheranostic agent that is safe, sensitive and highly selective in humans, which infers a future diagnostic tool and breakthrough targeted radiotherapy for glioblastoma patients," said Jingjing Zhang, M.D., Ph.D., of Peking Union Medical College Hospital, Beijing, China. "We believe this innovative use of 64Cu-EBRGD will significantly improve therapeutic efficacy and patient outcomes."

"64Cu-labeled EBRGD represents a viable model compound for therapeutic applications since 177Lu, 90Y or 225Ac can be substituted for 64Cu," said Deling Li, M.D., of Beijing Tiantan Hospital, Capital Medical University, Beijing, China. "We are currently studying the 177Lu homolog to treat glioblastoma and other αvβ3 integrin expressing cancers, including non-small cell lung, melanoma, renal and bone, and hope to build on the current wave of radiotherapies like 177Lu-DOTATATE."

For more information: www.snmmi.org

Related SNMMI20 Content:

SNMMI Channel

PSMA PET/CT Can Change Management in Recurrent Prostate Cancer

Total-body Dynamic PET Successfully Detects Metastatic Cancer

New PET Radiotracer Proven Safe in Imaging Malignant Brain Tumors

Targeted Radionuclide Therapy Enhances Prostate Cancer Response to Immunotherapies

New PET/MRI Approach Pinpoints Chronic Pain Location, Alters Management


Related Content

News | Radiation Therapy

September 28, 2023 — RefleXion Medical, a therapeutic oncology company, announced the company will showcase the ...

Time September 28, 2023
arrow
News | Breast Imaging

September 27, 2023 — Researchers at Weill Cornell Medicine have discovered that radiation therapy combined with two ...

Time September 27, 2023
arrow
Feature | Magnetic Resonance Imaging (MRI) | By Robert L. Bard, MD, and Lennard M. Gettz, EdD

Since the advent of the magnetic resonance imaging (MRI) exam on human patients in the late 1970s, this innovation ...

Time September 25, 2023
arrow
News | X-Ray

September 21, 2023 — Scientists in Moscow have successfully engineered a prototype detector for X-ray and PET/CT ...

Time September 21, 2023
arrow
Feature | Proton Therapy | By Christine Book

An overview of significant developments in proton therapy, over just the past six months, reinforces the pace of ...

Time September 21, 2023
arrow
News | Artificial Intelligence

September 20, 2023 — Medical imaging artificial intelligence (AI) company Annalise.ai has announced that the results ...

Time September 20, 2023
arrow
News | SNMMI

September 18, 2023 — The Society of Nuclear Medicine and Molecular Imaging (SNMMI), as a professional society ...

Time September 18, 2023
arrow
News | Artificial Intelligence

September 11, 2023 — Lunit, a leading provider of AI-powered solutions for cancer diagnostics and therapeutics, is ...

Time September 11, 2023
arrow
News | PET-CT

September 8, 2023 — Positron Corporation, a leading molecular imaging medical device company, is pleased to announce ...

Time September 08, 2023
arrow
News | PET-CT

September 7, 2023 — The groundbreaking AURA 10 specimen imager by Belgian MedTech pioneer XEOS has been cleared by the ...

Time September 07, 2023
arrow
Subscribe Now